Literature DB >> 11465084

Accelerator mass spectrometry in pharmaceutical research and development--a new ultrasensitive analytical method for isotope measurement.

R C Garner1.   

Abstract

Accelerator mass spectrometry (AMS) permits the measurement of elemental isotopes at the individual atom level. The main application of AMS in drug discovery and development will be in the analysis of 14-carbon (14C). The principle behind AMS is the separation of individual positively charged atoms through mass, charge and momentum differences. In order to obtain the high-energy charge state required for separation, negative atoms are accelerated through a high voltage field (up to 10 million volts) generated by a tandem Van de Graaff accelerator. In the middle of the accelerator, the outer valency electrons are stripped from the atom and the resulting charged species are separated and counted. For 14C, AMS counts the number of individual atoms rather than measuring radioactive decays. The result is that AMS is up to one million times more sensitive than decay counting. Radioactivity levels as low 0.0001 dpm can be detected using AMS. The exquisite sensitivity of AMS analysis means that much lower amounts of 14C can be used than for conventional counting methods. This makes it easier to use 14C for in vitro, preclinical and clinical research programmes. As 14C poses both a biological and environmental hazard, AMS permits much lower doses to be used. Human drug mass balance studies have been conducted with doses of 50 nanoCuries and below. Radioactive HPLC metabolite profiles of plasma extracts from subjects given nanoCurie doses of 14C-labelled drug have been obtained by injecting as little as 0.25 dpm onto an HPLC column. In studies of biologics, biosynthetically 14C-labelled recombinant protein has been produced with a specific radioactivity sufficient to conduct human clinical studies with AMS analysis. For one human recombinant protein an increase in sensitivity of 2,000-fold over ELISA was obtained with AMS measurement. AMS is an enabling technology that should prove of value in increasing human and environmental safety as well as allowing new research directions to be followed.

Entities:  

Mesh:

Year:  2000        PMID: 11465084     DOI: 10.2174/1389200003339054

Source DB:  PubMed          Journal:  Curr Drug Metab        ISSN: 1389-2002            Impact factor:   3.731


  9 in total

1.  Single and multiple dose intravenous and oral pharmacokinetics of the hedgehog pathway inhibitor vismodegib in healthy female subjects.

Authors:  Richard A Graham; Cornelis E C A Hop; Marie T Borin; Bert L Lum; Dawn Colburn; Ilsung Chang; Young G Shin; Vikram Malhi; Jennifer A Low; Mark J Dresser
Journal:  Br J Clin Pharmacol       Date:  2012-11       Impact factor: 4.335

Review 2.  Accelerator mass spectrometry-enabled studies: current status and future prospects.

Authors:  Ali Arjomand
Journal:  Bioanalysis       Date:  2010-03       Impact factor: 2.681

Review 3.  Mass balance studies, with a focus on anticancer drugs.

Authors:  Jan H Beumer; Jos H Beijnen; Jan H M Schellens
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 4.  Quantifying exploratory low dose compounds in humans with AMS.

Authors:  Stephen R Dueker; Le T Vuong; Peter N Lohstroh; Jason A Giacomo; John S Vogel
Journal:  Adv Drug Deliv Rev       Date:  2010-10-31       Impact factor: 15.470

Review 5.  Positron emission tomography microdosing: a new concept with application in tracer and early clinical drug development.

Authors:  Mats Bergström; Anders Grahnén; Bengt Långström
Journal:  Eur J Clin Pharmacol       Date:  2003-08-22       Impact factor: 2.953

Review 6.  Microdosing and drug development: past, present and future.

Authors:  Graham Lappin; Robert Noveck; Tal Burt
Journal:  Expert Opin Drug Metab Toxicol       Date:  2013-04-04       Impact factor: 4.481

7.  Observational infant exploratory [(14)C]-paracetamol pharmacokinetic microdose/therapeutic dose study with accelerator mass spectrometry bioanalysis.

Authors:  Colin R Garner; Kevin B Park; Neil S French; Caroline Earnshaw; Alessandro Schipani; Andrew M Selby; Lindsay Byrne; Sarah Siner; Francis P Crawley; Wouter H J Vaes; Esther van Duijn; Rianne deLigt; Heili Varendi; Jane Lass; Grzegorz Grynkiewicz; Wioletta Maruszak; Mark A Turner
Journal:  Br J Clin Pharmacol       Date:  2015-06-01       Impact factor: 4.335

Review 8.  Opportunities in low-level radiocarbon microtracing: applications and new technology.

Authors:  Le Thuy Vuong; Qi Song; Hee Joo Lee; Ad F Roffel; Seok-Ho Shin; Young G Shin; Stephen R Dueker
Journal:  Future Sci OA       Date:  2015-12-23

9.  Human mass balance study of the novel anticancer agent ixabepilone using accelerator mass spectrometry.

Authors:  J H Beumer; R C Garner; M B Cohen; S Galbraith; G F Duncan; T Griffin; J H Beijnen; J H M Schellens
Journal:  Invest New Drugs       Date:  2007-03-09       Impact factor: 3.850

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.